Michael M.
- Country
- Germany
- Department
- Kinder-Uni-Klinik Ostbayern (KUNO); KLINIK UND POLIKLINIK FÜR KINDER- UND JUGENDMEDIZIN
Research Overview
- Efficacy, Safety, and Pharmacokinetics of Ustekinumab in Pediatric Patients with Moderate to Severe Crohn's Disease: A Phase 3 Randomized Controlled Trial
- Efficacy, Safety, and Pharmacokinetics of Ustekinumab in Pediatric Patients with Moderate to Severe Ulcerative Colitis: A Phase 3 Randomized Controlled Trial
Data & Insights
Has run more than one trial at 19 of 23 partner sites.
Specializations
Pediatric Gastroenterology
The investigator specializes in treating severe inflammatory bowel conditions in pediatric populations, with particular focus on ulcerative colitis and Crohn's disease.
- Inflammatory Bowel Disease Management
- Pediatric Gastrointestinal Disorders
- Advanced Therapeutic Approaches
Their research encompasses innovative treatment approaches for managing moderate to severe gastrointestinal conditions in young patients.
Therapeutic Applications
The investigator focuses on evaluating novel therapeutic interventions, particularly examining biological treatments for inflammatory bowel conditions in pediatric patients.
- Intravenous Induction Therapy
- Subcutaneous Maintenance Treatment
- Long-term Disease Management
Their work involves assessing treatment efficacy and safety profiles in young patients with chronic gastrointestinal conditions.
Clinical Pharmacology
The investigator studies pharmacokinetics in pediatric populations, focusing on understanding medication exposure and response in young patients with inflammatory bowel conditions.
- Drug Exposure Assessment
- Treatment Response Evaluation
- Safety Profile Analysis
Their research includes monitoring clinical remission patterns and therapeutic outcomes in pediatric gastrointestinal disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.